



(11) Publication number: **0 044 168 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

- (45) Date of publication of patent specification: **22.05.85** (51) Int. Cl.⁴: **C 07 K 7/10, A 61 K 37/28**
 (21) Application number: **81302978.2**
 (22) Date of filing: **30.06.81**

(54) **The use of peptides as medicaments and certain novel peptides.**

(30) Priority: **01.07.80 DK 2831/80**

(43) Date of publication of application:
20.01.82 Bulletin 82/21

(45) Publication of the grant of the patent:
22.05.85 Bulletin 85/21

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(50) References cited:
US-A-3 642 763

THE JOURNAL OF BIOLOGICAL CHEMISTRY,
 vol. 247, no. 4, February 25, 1972, I.D.
 GOLDFINE et al. "Glucagon receptors in beta-
 cells. Binding of 125I-glucagon and activation
 of adenylate cyclase", pages 1211-1218
 Schröder et al.: "The Peptide", Academic Press
 N.Y. and London vol. II. p. 254-260
 I. Biol. Chem. 247, 2132
 I. Biol. Chem. 247, 977
 Metabolism 25 Suppl. 1, 1315/6
 Biochem. I. 104(1967) 17.

(78) Proprietor: **NOVO INDUSTRI A/S**
Novo Allé
DK-2880 Bagsvaerd (DK)

(72) Inventor: **Lundt, Behrend Friedrich**
118, Rosenhaven
DK-2980 Kokkedal (DK)
 Inventor: **Jorgensen, Karin Damm**
12 Skovvej
DK-2950 Vedbaek (DK)
 Inventor: **Johansen, Nils Langeland**
45 Niels W. Gades Gade
DK-2100 Kobenhavn O (DK)
 Inventor: **Gronvald, Frederik Christian**
19, Dronningeengen
DK-2950 Vedbaek (DK)
 Inventor: **Frandsen, Erik Kai**
12, Norasvej
DK-2920 Charlottenlund (DK)
 Inventor: **Moody, Alister James**
17B, Skovbovej
DK-2800 Lyngby (DK)
 Inventor: **Markussen, Jan**
7, Kikudbakken
DK-2730 Herlev (DK)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European patent convention).

EP 0 044 168 B1


⑦ Representative: Brown, John David et al
FORRESTER & BOEHMERT Widenmayerstrasse
4/I
D-8000 München 22 (DE)

Description


The present invention relates to the use of peptides of the general formula I



wherein R¹ represents



and R^2 represents OH, the peptide chain



or a corresponding peptide chain or amino acid which is identical with the two last-mentioned peptide chains with the proviso that one or more of the amino acid(s) of the said two last-mentioned peptide chains has/have been omitted, or salts thereof. Compounds of formula I show interesting and surprising pharmacological properties.

Glucagon, a polypeptide hormone consisting of 29 amino acids, is known to possess several pharmacological effects. The use of glucagon for the treatment of hypoglycemia is based upon its metabolic effects. Furthermore, glucagon exerts a spasmolytic effect on smooth muscle and an inhibitory effect on gastric acid secretion. It has now, surprisingly, been found that compounds of formula I as to quantity possess a similar spasmolytic effect and a similar inhibitory effect on gastric acid secretion as that of glucagon, although compounds of formula I show no or minor, negligible metabolic effect. Hence, compounds of formula I are considered superior to glucagon when only a spasmolytic effect or an inhibition of gastric acid secretion is desired.

Glucagon₁₋₂₁, glucagon₁₋₂₆ and des(22-26)glucagon have for instance been found to have almost the same potency as glucagon as regards inhibitor effect on the amplitude of the contractions of the electrically stimulated guinea pig ileum *in vitro*. 10^{-5} M glucagon caused $83 \pm 4\%$ ($\bar{X} \pm \text{sd}$, $N=3$) inhibition compared to $78 \pm 5\%$ for glucagon₁₋₂₁. The effects of 10^{-6} M was $50 \pm 3\%$ and $52 \pm 5\%$, respectively, and of 10^{-7} M: $27 \pm 3\%$ for either peptide.

Furthermore, glucagon₁₋₂₁ has almost the same potency as glucagon with respect to reducing effect on intestinal motility in rabbits *in vivo*. 100 to 200 µg glucagon and 77 to 154 µg glucagon₁₋₂₁ administered intravenously as a bolus to anaesthetised rabbits of 2.5 to 3.0 kg body weight caused an inhibition of intestinal motility beginning 1 minute after the administration and lasting for about 10 minutes.

The metabolic effects of glucagon₁₋₂₁, glucagon₁₋₂₆ and des(22-26)glucagon, as exemplified by their lipolytic effect on rat free fat cells *in vitro* and their effect on the activation of the adenylate cyclase *in vitro*, are negligible compared with the metabolic effects of glucagon. No metabolic effects have been found after administration to rats *in vivo*.

It has been shown that glucagon releases insulin from the isolated perfused rat pancreas but glucagon₁₋₂₁ has no such effect when it is infused to the same concentration as glucagon. Furthermore, glucagon₁₋₂₁—contrary to glucagon—does not cause hyperglycemia or release insulin *in vivo* in rats.

45 In cats with chronic gastric fistulas glucagon₁₋₂₁ as well as glucagon inhibit pentagastrin stimulated gastric acid secretion. 1 µg/kg pentagastrin subcutaneously administered to gastric fistula cats caused an increase in gastric acid secretion of 856±71 µEq (Eq designates equivalent) acid (\bar{X} ±S.E.M., N=18). When 2 µg/kg glucagon₁₋₂₁ was administered subcutaneously at the same time as 1 µg/kg pentagastrin the increase in acid output was only 417±104 µEq acid (N=6).

Glucagon₁₋₂₁ and glucacon are almost equipotent as regards relaxing effect on a submaximally contracted rabbit gall bladder preparation *in vitro*, and both compounds cause an increase in gall flow in rats *in vivo*. When a gall bladder strip was contracted with 0.1 µg/ml cholecystochinin octapeptide 10⁻⁶M glucagon caused 39% relaxation and 10⁻⁶M glucagon₁₋₂₁ caused 41% relaxation. The ED₅₀ value was for both peptides 2.7×10⁻⁶ M. Therefore, compounds of formula I may have a potential utility in the treatment of biliary tract and—because of their general spasmolytic properties—possibly urinary *calculi* patients. As regards this utility, the fact that compounds of formula I have no or minor, negligible metabolic effect must be a considerable advantage.

Hence, a compound of formula I or a salt thereof may be used as a therapeuticum or a diagnosticum. The indication areas for use of the compounds of formula I and salts thereof in therapy will be, for example, biliary tract and urinary tract *calculi*, spasms in the digestive system and gastro-duodenal ulcers. The indication areas for use of the compounds of formula I and salts thereof for diagnostic purposes will be investigational techniques such as radiology (X-ray examination), endoscopy (direct observation of the gastro-intestinal tract) and hysterosalpingography.

65 Compounds of formula I are converted into pharmaceutical preparations and administered, preferably to humans, in analogy with known methods.

Compounds of formula I and salts thereof can, as diagnosticum, be used in analogy with the use of glucagon for the same purpose. Compounds of formula I and salts thereof can be administered intravenously, intramuscularly or subcutaneously at dosages in the range of from about 1 to 1000 µg/kg body weight, preferably from about 10 to 100 µg/kg body weight, although a lower or higher dosage may be administered. The required dosage will depend on the severity of the condition of the patient and the duration of treatment. A higher dosage may be used for biliary tract and urinary tract *calculi* patients and gastro-duodenal ulcer patients and, in these cases, multiple dosages of the compounds may be administered, for example, parenterally (for example as a continuous infusion) or by the nasal or rectal route.

Compounds of formula I may possibly be administered orally, e.g., by the use of special additives. For the purpose of parenteral administration, compounds of formula I are dissolved in distilled water and the pH-value is adjusted to about 6 to 8. In order to facilitate the lyophilization process resulting in a suitable product lactose could be added to the solution. The solution is sterile filtered and filled in vials. Thereafter, the solutions are lyophilized and the vials are sealed under aseptic conditions.

For the purpose of nasal administration a solution in a nasal spraying device or nebulisator is used. The compounds of formula I are dissolved in distilled water, the pH-value is adjusted to about 6 to 8 by adding sodium phosphate and citric acid as buffer. Sodium chloride, sorbitol and glycerol are used to obtain an isotonic solution with a suitable viscosity. The solution is administered by the use of a suitable nebulisator or plast spray. The solution may be preserved by the use of known preservatives and a known surfactant may be added.

For the purpose of nasal administration by the use of dose aerosol spray the peptides are mixed with suitable constituents and a mixture of halogenocarbons, i.e. monofluorotrichloromethane, difluorodichloromethane and tetrafluorodichloroethane, in order to obtain a mixture with a vapour pressure producing a well defined single dose when the mixture is administered by the use of a dose aerosol spray.

The compounds of formula I are preferably used by nasal administration in a dosage range between about 0.1 and 100 µg/kg body weight, preferably between 1 and 10 µg/kg body weight, per single dose. This dose could be administered several times per day.




For the purpose of rectal administration suppositories are produced by admixing compounds of formula I, with an inactive constituent such as cocoa butter or with a base such as Polysorbate 85, propylene glycol monostearate and white bee's wax.

Compounds of formula I and salts thereof can be prepared by methods which are generally known in peptide synthesis. Briefly, compounds of formula I can be built up from a protected glucagon fragment, e.g. protected glucagon₁₋₁₅, and a protected peptide containing the remaining amino acids of the desired compound of formula I. The preparation of protected glucagon₁₋₁₅ is described in Res. Discl. 1979, 247. Peptides containing more than amino acids Nos. 16-21 in glucagon can be built up from a protected glucagon fragment, e.g. protected glucagon₁₆₋₂₁ and a protected peptide containing the remaining amino acids. The use of suitable protecting groups and activations during the peptide synthesis is known to the skilled art worker. It is desired to use protecting groups which can easily be removed.

Thus, glucagon₁₋₂₁, glucagon₁₋₂₆ and des(22-26)-glucagon can be prepared by coupling the protected glucagon fragment:



with the protected glucagon fragments:



respectively, by the mixed anhydride method using isobutyl chloroformate. The fully protected peptides so obtained can be deprotected under acid conditions, e.g. by treatment with trifluoroacetic acid containing 10% 1,2-ethanedithiol. The crude peptides can be purified by ion-exchange chromatography, e.g. QAE-Sephadex A-25, followed by a desalting procedure, e.g. gel-filtration on Sephadex G-25. The purified peptides can be isolated by lyophilization. The intermediate protected glucagon fragments IV and V can be prepared by coupling, using the mixed anhydride procedure, the protected glucagon fragment:

Bpoc-Ser(Bu¹)-Arg(HBr)-Arg(HBr)-Ala-Gln-Asp(OBu¹)-OH
20

(VI)

with the protected glucagon fragments:

5

H-Phe-Val-Gln-Trp-Leu-OBu¹
25

(VII)

H-Met-Asn-Thr(Bu¹)-OBu¹

(VIII)

10

respectively, whereupon the N-terminal Bpoc group can be removed selectively under mild acid conditions, e.g. by treatment with HCl (0.2N) in methanol/N,N-dimethylformamide.

The protected peptide fragments III, VI, VII and VIII were synthesized by stepwise chain elongation applying conventional procedures such as the active ester or mixed anhydrid methods for coupling.

15

Peptides of formula I, wherein R² represents the peptide chain

Phe-Val-Gln-Trp-Leu
25

or

20

-Met-Asn-Thr

in which one or more amino acid(s) has/have been omitted, can be prepared in a similar manner as described above with the exception that one or more of the amino acid(s) in question has/have been omitted in the protected peptide fragments VII and VIII.

25

A process for preparing glucagon₁₋₂₁ has been described in J.Biol.Chem. 247, 2133, by digesting porcine, bovine or sheep glucagon with carboxypeptidase A. Glucagon₁₋₂₆ is known from Metabolism 25, Suppl. 1, 1315.

A preferred subclass of compounds of formula I is compounds wherein the amino acid sequence is identical with a continuous part of the amino acid sequence of glucagon. As examples of specific compounds, within this class of compounds, compounds of formula I, wherein R² is Phe, Val, Gln, Trp, Leu, Met, Asn or Thr, can be mentioned. A preferred compound of formula I is glucagon₁₋₂₁, because it shows superior pharmacological properties and because it can easily be obtained, e.g. from natural glucagon.

30

Furthermore, the present invention relates to novel compounds of the general formula I'

R¹-R'²

wherein R¹ is as defined above, and R'² has the same meaning as R², provided that R'² does not represent

40

-Phe-Val-Gln-Trp-Leu or OH,
25

or a salt thereof.

Briefly, compounds of formula I' may be prepared by treating a compound of the general formula

45

R³-R⁴-OBu¹

(IX)

wherein R³ represents

50

Adoc-His(Adoc)-Ser(Bu¹)-Gln-Gly-Thr(Bu¹)-Phe-Thr(Bu¹)-
5

Ser(Bu¹)-Asp(OBu¹)-Tyr(Bu¹)-Ser(Bu¹)-Lys(Boc)-Tyr(Bu¹)-Leu-
10

55

Asp(OBu¹)-Ser(Bu¹)-Arg(HX)-Arg(HX)-Ala-Gln-Asp(OBu¹)-,
15 20

R⁴ represents the peptide moiety

60

-Phe-Val-Gln-Trp-Leu-
25

from which one or more of the amino acid(s) has/have been omitted, the peptide moiety

65

-Met-Asn-Thr(Bu¹)-

or corresponding peptide moieties which are identical with said moiety with the proviso that one or more of the amino acid(s) has/have been omitted, and X represents chlorine or bromine, with an acid such as trifluoroacetic acid.

As examples of salts of compounds of formula I, for example sodium, potassium, magnesium, calcium and zinc salts and acid addition salts with organic or inorganic acids such as formic acid, methanesulfonic acid, hydrochloric acid and sulphuric acid can be mentioned. Preferred salts of compounds of formula I are physiologically and pharmaceutically acceptable salts.

The present invention also relates to a pharmaceutical composition comprising a compound of formula I or a salt thereof and one or more pharmaceutically acceptable carrier(s), diluent(s) preferably water, and/or excipient(s). As examples of such carriers conventional preservatives, e.g. methyl or propyl p-hydroxybenzoate, and sodium chloride can be mentioned.

Any novel feature or combination of features described herein is considered essential.

The nomenclature used herein complies with that stated in J. Biol.Chem. 247, 977, and Biochem. J. 104, 17. However, for the sake of brevity, glucagon-(1—21)-benceicosapeptide herein has been designated glucagon₁₋₂₁, glucagon-(1—26)-hexacosapeptide has been designated glucagon₁₋₂₆ and des-pentapeptide-(22—26)-glucagon has been designated des(22—26)glucagon. Bpoc represents 1-(biphenyl-4-yl)-1-methylethoxycarbonyl, Adoc represents 1-adamantyloxycarbonyl, Bu^t represents tertiary butyl, and Boc represents tert-butyloxycarbonyl.

The following examples which, however, are not considered to be limiting are presented to illustrate the invention.

Example 1
des(22—26)glucagon

1 g of

Adoc-His(Adoc)-Ser(Bu^t)-Gln-Gly-Thr(Bu^t)-Phe-Thr(Bu^t)-
5

-Ser(Bu^t)-Asp(OBu^t)-Tyr(Bu^t)-Ser(Bu^t)-Lys(Boc)-Tyr(Bu^t)-Leu-
10

-Asp(OBu^t)-Ser(Bu^t)-Arg(HBr)-Arg(HBr)-Ala-Gln-Asp(OBu^t)-Met-Asn-Thr(Bu^t)-OBu^t
15 20

is dissolved in 25 ml of trifluoroacetic acid containing 10% 1,2-ethanedithiol and the reaction mixture is left at 15°C for 3 hours. Thereafter, 200 ml of tetrahydrofuran is added slowly and the precipitate is isolated, washed with tetrahydrofuran and dried *in vacuo*. The resulting product may be purified by ion-exchange chromatography on QAE Sephadex A-25 and desalted by gel-filtration on Sephadex G-25.

Example 2

A preparation for parenteral administration containing 1 mg of glucagon₁₋₂₁ per ml may be prepared as follows:

1 g of glucagon₁₋₂₁ and 99 g of lactose are dissolved in 1 litre of distilled water and the pH-value is adjusted to 7.0. The solution is thereafter sterile filtered. The sterile solution is filled in 10 ml vials in such a way that each vial contains 1.0 ml of the solution. Thereafter, the solutions are lyophilized and the vials are sealed under aseptic conditions.

The preparation in any of the vials is to be dissolved in 1.0 ml of sterile, isotonic water before administration.

Example 3

A preparation for parenteral administration containing 10 mg of glucagon₁₋₂₁ per ml may be prepared as follows:

10 g of glucagon₁₋₂₁ and 90 g of lactose are dissolved in 1 litre of distilled water and the solution is prepared analogously to the method described in Example 2.

Example 4

Rectal suppositories are prepared by admixing 1 mg of glucagon₁₋₂₁ with 4 g of cocoa butter.

Example 5

A nasal plast spray may be prepared as follows:

0.5 g of glucagon₁₋₂₁ is dissolved in about 95 ml of 0.01 M phosphate buffer (pH-value: 7.4) which is made isotonic by the addition of glycerol. The solution is preserved by the addition of 0.01% benzalkonium chloride and 0.05% EDTA whereafter 0.5% polyoxysorbate is added. An isotonic phosphate buffer is added in order to give a resulting volume of 100 ml and the solution is sterile filtered. 15 ml of said solution is filled in a plast spray giving 0.5 mg of glucagon₁₋₂₁, when activated.

Experiment A: Spasmolytic effect

One male rabbit weighing 2.56 kg was anaesthetized with nembutal after an overnight fast. The position of the balloon used for measurement of intestinal motility was 1 meter from pylorus in the jejunum. The motility was registered before and after intravenous administration of 77 μg glucagon₁₋₂₁ in 1 ml 0.9% saline containing 0.1% human serum albumin. The effect obtained was nearly complete atonia of the intestine. The onset of effect was 1 minute after the administration and the duration of effect was 11 minutes.

Experiment B: Spasmolytic effect

A male rabbit weighing 2.32 kg was treated as described in Experiment A with the following dosages: 77 μg glucagon₁₋₂₁ in 1 ml of the solution stated in Experiment A intravenously caused no detectable spasmolytic effect.

154 μg glucagon₁₋₂₁ in 1 ml of the solution in Experiment A intravenously had a questionable effect. 308 μg glucagon₁₋₂₁ in 1 ml of the above solution had a distinct spasmolytic effect causing nearly complete atonia. The onset of the effect was 2½ minutes and the duration of the effect was 6 minutes.

For comparison glucagon was administered to the same rabbit. 200 μg glucagon intravenously had no detectable effect, however, 400 μg gave a distinct effect comparable to the effect caused by 308 μg glucagon₁₋₂₁.

Experiment C: Gastric acid inhibitory effect

In a male cat weighing approx. 4.5 kg equipped with a cronic gastric fistula the gastric acid secretion was stimulated with 4.5 μg pentagastrin (Peptavlon®) in a volume of 1 ml 0.9% saline containing 0.1% human serum albumin subcutaneously in the neck. In 8 experiments 1 ml placebo (0.9% saline with 0.1% human serum albumin) was administered subcutaneously through another cannula in the neck at the same time as the administration of pentagastrin. In 2 experiments 9 μg of glucagon₁₋₂₁ in 1 ml of the above solution was administered simultaneously with the administration of pentagastrin. Gastric acid secretion was collected over periods of 15 minutes and titrated with 0.01N NaOH. The increase in acid secretion after the administration of pentagastrin was calculated as μEq acid excreted over 1½ hrs. after the administration subtracting the basal acid secretion before administration of pentagastrin. After administration of 4.5 μg pentagastrin plus placebo the increase in gastric acid secretion was $729 \pm 89 \mu\text{Eq}$ acid ($\bar{X} \pm \text{S.E.M.}$, N=8). 4.5 μg pentagastrin+9 μg glucagon₁₋₂₁ caused an increase in acid secretion of 238 μEq in one experiment and 231 μEq in another experiment.

Experiment D: Effect on bile flow

In rabbits with catheters in the bile duct the administration of glucagon and glucagon₁₋₂₁ caused a decrease in gall flow immediately after the administration, probably reflecting a decrease in the tonus of the gall bladder. This decrease in flow was followed by an increase in bile flow to quantities higher than before the administration reflecting an increase in production of bile.

One rex rabbit weighing 2.0 kg was equipped with a catheter in the bile duct during nembutal anaesthesia on the day before the experiment. On the day of the experiment the bile was collected for periods of 15 minutes.

The results obtained appear from the following table:

Sampling periods, minutes	0—15	15—30	30—45	45—60	60—75	75—90
Amount of bile, ml	1.20	1.50	1.40	0.20	0.25	3.30

Sampling periods, minutes	90—105	105—120	120—135	135—150	150—165	165—180
Amount of bile, ml	2.80	2.00	0.40	1.65	2.05	3.50

Sampling periods, minutes	180—195	195—210	210—225	225—240	240—255	255—270
Amount of bile, ml	1.10	1.50	1.50	1.35	1.70	1.75

After 45 minutes 200 µg glucagon was administered subcutaneously in 1 ml of 0.9% saline containing 0.1% human serum albumin. After 120 minutes 154 µg glucagon₁₋₂₁ was administered subcutaneously in 1 ml of the above solution. After 195 minutes the placebo (*vide* Experiment C) was administered.

Experiment E: Acute toxicity study


10 mg glucagon₁₋₂₁ administered intravenously as a bolus to NMRI mice weighing 20 g (i.e. a dose of 500 mg/kg body weight) had no adverse effects. No deaths occurred.

Claims for the Contracting States: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. A compound for use as a medicament or diagnosticum, of the general formula I



wherein R¹ represents



and R² represents OH, the peptide chain



or



or a corresponding peptide chain or amino acid which is identical with the two last-mentioned peptide chains with the proviso that one or more of the amino acid(s) of the said two last-mentioned peptide chains has/have been omitted, or a salt of such a compound.

2. A compound according to Claim 1, for use as a medicament or diagnosticum, wherein the compound is used as a spasmolyticum or a gastric acid secretion depressing agent.

3. A compound according to Claim 1 for use as a medicament or diagnosticum, wherein the compound is used for treatment of spasms in the digestive system, for treatment of biliary tract and urinary tract calculi and/or for treatment of gastro-duodenal ulcers.

0 044 168

4. A compound according to any one of Claims 1 to 3 for use as a medicament or diagnosticum, wherein R² represents OH,

-Phe-Val-Gln-Trp-Leu
25

or

-Met-Asn-Thr.

5. A compound according to any one of Claims 1 to 4 for use as a medicament or diagnosticum, wherein R² represents OH.

6. A pharmaceutical composition, which comprises an effective amount of a compound of formula I of Claim 1, or a salt thereof, in association with a suitable physiologically acceptable carrier, diluent and/or excipient.

7. A pharmaceutical composition according to Claim 6, which comprises from 7.5 to 75,000 µg, preferably from 75 to 7500 µg, of a compound of formula I, or salt thereof, per dosage unit.

8. A pharmaceutical composition according to Claim 6 or 7, wherein R² represents OH,

-Phe-Val-Gln-Trp-Leu
25

or

-Met-Asn-Thr.

9. A pharmaceutical composition according to Claim 6 or 7, wherein R² is OH.

10. A novel compound of the general formula I'

R¹-R'² (I')

wherein R¹ is as defined in Claim 1 and R'² has the same meaning as R² as defined in Claim 1, provided that R'² does not represent

-Phe-Val, -Phe-Val-Gln-Trp, -Phe-Val-Gln-Trp-Leu
25

or OH, or a salt of such a compound.

Claims for the Contracting State: AT

1. A method of preparing a pharmaceutical preparation for use as a medicament or diagnosticum, which method comprises incorporating in a pharmaceutical preparation a compound of the general formula I

R¹-R² (I)

wherein R¹ represents

His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-
5 10 15 20

and R² represents OH, the peptide chain,

-Phe-Val-Gln-Trp-Leu
25

or

-Met-Asn-Thr

or a corresponding peptide chain or amino acid which is identical with the two last-mentioned peptide chains, with the proviso that one or more of the amino acid(s) of the said last-mentioned peptide chains has/have been omitted, or a salt of such a compound.

2. A method according to Claim 1, wherein the pharmaceutical preparation is for use as a spasmolyticum or a gastric acid secretion depressing agent.

3. A method according to Claim 1, wherein the pharmaceutical preparation is for use for treatment of spasms in the digestive system, for treatment of biliary tract and urinary tract *calculi* and/or for treatment of gastro-duodenal ulcers.

4. A method according to any one of Claims 1 to 3, wherein R² represents OH,

0 044 168

-Phe-Val-Gln-Trp-Leu
25

or

-Met-Asn-Thr.

5

5. A method according to any one of Claims 1 to 4, wherein R² represents OH.

6. A pharmaceutical composition, which comprises an effective amount of a compound of formula I of Claim 1, or a salt thereof, in association with a suitable physiologically acceptable carrier, diluent and/or excipient.

10 7. A pharmaceutical composition according to Claim 6, which comprises from 7.5 to 75,000 µg, preferably from 75 to 7500 µg, of a compound of formula I, or salt thereof, per dosage unit.

8. A pharmaceutical composition according to Claim 6 or 7, wherein R² represents OH,

15

-Phe-Val-Gln-Trp-Leu
25

or

-Met-Asn-Thr.

20

9. A pharmaceutical composition according to Claim 6 or 7, wherein R² is OH.

10. A novel compound of the general formula I'

R¹—R'² (I')

25 wherein R¹ is as defined in Claim 1 and R'² has the same meaning as R² as defined in Claim 1, provided that R'² does not represent

Phe-Val, Phe-Val-Gln-Trp, -Phe-Val-Gln-Trp-Leu
25

30 or OH, or a salt of such a compound.

11. A process for the preparation of a compound of the formula I' or a salt thereof, which comprises preparing the same from the parent L-amino acids, whereafter a compound of formula I', if desired, is converted into a salt thereof.

35 12. A process for the preparation of a compound of the formula I', or a salt thereof, wherein a compound of the general formula

R³—R⁴-OBu^t (IX)

wherein R³ represents

40

Adoc-His(Adoc)-Ser(Bu^t)-Gln-Gly-Thr-(Bu^t)-Phe-Thr(Bu^t)-
5

Ser(Bu^t)-Asp(OBu^t)-Tyr(Bu^t)-Ser(Bu^t)-Lys(Boc)-Tyr(Bu^t)-
10

45

Leu-Asp(OBu^t)-Ser(Bu^t)-Arg(HX)-Arg(HX)-Ala-Gln-Asp(OBu^t)-,
15 20

50 R⁴ represents the peptide moiety

-Phe-Val-Gln-Trp-Leu-
25

55 from which one or more of the amino acid(s) has/have been omitted, the peptide moiety -Met-Asn-Thr(Bu^t)- or corresponding peptide moieties which are identical with said moiety with the proviso that one or more of the amino acid(s) has/have been omitted, and X represents chlorine or bromine, is treated with an acid, such as trifluoroacetic acid, whereafter the resulting compound, if desired, is converted into a salt thereof.

60 Patentansprüche für die Vertragsstaaten: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Verbindung der allgemeinen Formel I,

R¹—R² (I)

65 zur Verwendung als Arzneimittel oder als Diagnostikum, worin R¹

0 044 168

His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-
5 10 15 20

bedeutet und R² OH, die Peptidkette

5 -Phe-Val-Gln-Trp-Leu
25

oder

-Met-Asn-Thr

10 oder eine entsprechende Peptidkette oder Aminosäure, die mit den beiden letztgenannten Peptidketten identisch ist, mit der Massgabe, dass eine oder mehrere Aminosäuren der zwei letztgenannten Peptidketten weggelassen sind, bedeutet, oder ein Salz einer solchen Verbindung.

2. Verbindung nach Anspruch 1 zur Verwendung als Arzneimittel oder als Diagnostikum, wobei die Verbindung als Spasmolytikum oder als Mittel zur Hemmung der Magensäuresekretion verwendet wird.

15 3. Verbindung nach Anspruch 1 zur Verwendung als Arzneimittel oder als Diagnostikum, wobei die Verbindung zur Behandlung von Spasmen im Verdauungstrakt, zur Behandlung von Steinbildungen im Gallen- und Harntrakt und/oder zur Behandlung von Magen- und/oder Zwölffingerdarm-Geschwüren verwendet wird.

20 4. Verbindung nach einem der Ansprüche 1 bis 3 zur Verwendung als Arzneimittel oder als Diagnostikum, worin R² OH,

-Phe-Val-Gln-Trp-Leu
25

oder

25 -Met-Asn-Thr

bedeutet.

5. Verbindung nach einem der Ansprüche 1 bis 4 zur Verwendung als Arzneimittel oder als Diagnostikum, worin R² OH bedeutet.

30 6. Pharmazeutische Zubereitung, welche eine wirksame Menge einer Verbindung der Formel (I) nach Anspruch 1 oder ein Salz davon in Verbindung mit einem geeigneten physiologisch annehmbaren Träger, Verdünnungsmittel und/oder Excipiens enthält.

7. Pharmazeutische Zubereitung nach Anspruch 6, welche zwischen 7,5 und 75'000 µg, vorzugsweise zwischen 75 und 7500 µg, einer Verbindung der Formel (I) oder eines Salzes davon je Dosierungseinheit enthält.

35 8. Pharmazeutische Zubereitung nach Anspruch 6 oder 7, worin R² OH,

-Phe-Val-Gln-Trp-Leu
25

oder

-Met-Asn-Thr

bedeutet.

9. Pharmazeutische Zubereitung nach Anspruch 6 oder 7, worin R² OH bedeutet.

45 10. Neue Verbindung der Formel I'

R¹-R'² (I')

worin

R¹ die gleiche Bedeutung hat wie im Anspruch 1 und

50 R'² die gleiche Bedeutung wie die Bedeutung von R² im Anspruch 1 hat, mit der Massgabe, dass R'² nicht -Phe-Val, -Phe-Val-Gln-Trp,

-Phe-Val-Gln-Trp-Leu
25

55

oder OH oder ein Salz einer solchen Verbindung bedeutet.

Patentansprüche für den Vertragsstaat: AT

60 1. Verfahren zur Herstellung einer pharmazeutischen Zubereitung zur Verwendung als Arzneimittel oder Diagnostikum, welches Verfahren die Zugabe einer Verbindung der allgemeinen Formel I

R¹-R² (I)

65

worin R^1

His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-

5 bedeutet und
R² OH, die Peptidkette

-Phe-Val-Gln-Trp-Leu
25

oder -Met-Asn-Thr oder eine entsprechende Peptidkette oder Aminosäure, die mit den beiden letztgenannten Peptidketten identisch ist, mit der Massgabe, dass eine oder mehrere Aminosäuren der zwei letztgenannten Peptidketten weggelassen sind, bedeutet, oder eines Salzes einer solchen Verbindung
15 zu einer pharmazeutischen Zubereitung umfasst.

2. Verfahren nach Anspruch 1, wobei die pharmazeutische Zubereitung als Spasmolytikum oder als Mittel zur Hemmung der Magensäuresekretion verwendet wird.

3. Verfahren nach Anspruch 1, wobei die pharmazeutische Zubereitung zur Verwendung zur Behandlung von Spasmen im Verdauungstrakt, zur Behandlung von Steinbildungen im Gallen- und Harntrakt und/oder zur Behandlung von Magen- und/oder Zwölffingerdarm-Geschwüren vorgesehen ist.

4. Verfahren nach einem der Ansprüche 1 bis 3, worin R^2 OH,

-Phe-Val-Gln-Trp-Leu
25

25 oder

-Met-Asn-Thr

bedeutet.

5. Verfahren nach einem der Ansprüche 1 bis 4, worin R^2 OH bedeutet.

30 6. Pharmazeutische Zubereitung, welche eine wirksame Menge einer Verbindung der Formel (II) nach Anspruch 1 oder ein Salz davon in Verbindung mit einem geeigneten physiologisch annehmbaren Träger, Verdünnungsmittel und/oder Excipients enthält.

7. Pharmazeutische Zubereitung nach Anspruch 6, welche zwischen 7,5 und 75'000 µg, vorzugsweise zwischen 75 und 7500 µg, einer Verbindung der Formel (I) oder eines Salzes davon je Dosierungseinheit enthält.

35 zwischen 70 und 7500 µg, einer Verbindung der Formel (I) oder eines Salzes davon je Dosierungseinheit enthält.

8. Pharmazeutisch Zubereitung nach Anspruch 6 oder 7, worin R^2 OH.

-Phe-Val-Gln-Trp-Leu
25

40 oder

-Met-Asn-Thr

bedeutet.

45 9. Pharmazeutische Zubereitung nach Anspruch 6 oder 7, worin R² OH bedeutet.
10. Neue Verbindung der Formel I'

10. Neue Verbindung der Formel I'

$$R^1-R'^2 \quad (I')$$

50 warin

R¹ die gleiche Bedeutung hat wie im Anspruch 1 und

R^2 die gleiche Bedeutung wie die Bedeutung von R^2 im Anspruch 1 hat, mit der Massgabe, dass R^2 nicht -Phe-Val, -Phe-Val-Gln-Trp.

55 -Phe-Val-Gln-Trp-Leu
25

oder OH oder ein Salz einer solchen Verbindung bedeutet.

60 11. Verfahren zur Herstellung einer Verbindung der Formel (I') oder eines Salzes davon, umfassend die Herstellung dieser Verbindung, ausgehend von den Stamm-L-Aminosäure, worauf eine Verbindung der Formel (I'), sofern erwünscht, in ein Salz davon umgewandelt wird.

12. Verfahren zur Herstellung einer Verbindung der Formel (I') oder eines Salzes davon, bei welchem eine Verbindung der allgemeinen Formel (IX)

$$65 \qquad \qquad \qquad R^3-R^4-OBu^t \qquad \qquad \qquad (IX)$$

worin
R³

Adoc-His(Adoc)-Ser(Bu³)-Gln-Gly-Thr(Bu³)-Phe-Thr(Bu³)-Ser(Bu³)-Asp(OBu³)-Tyr(Bu³)-
5 10

Ser(Bu³)-Lys(Boc)-Tyr(Bu³)-Leu-Asp(OBu³)-Ser(Bu³)-Arg(HX)-Arg(HX)-Ala-Gln-Asp(OBu³)-,
15 20

R⁴ den Peptidanteil

-Phe-Val-Gln-Trp-Leu-,
25

von dem eine oder mehrere Aminosäuren weggelassen sind, den Peptidanteil -Met-Asn-Thr(Bu³)- oder
15 entsprechende Peptidanteile, welche mit den genannten Anteilen identisch sind mit der Massgabe, dass
eine oder mehrere Aminosäuren weggelassen sind, und X chlor oder Brom bedeuten,
mit einer Säure wie Trifluoressigsäure behandelt und danach gewünschtenfalls die resultierende
Verbindung in ein Salz davon umgewandelt wird.

20 **Revendications pour les Etats Contractants: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE**

1. Composé de formule générale I

R¹—R² (I)

25 à titre de médicament ou d'agent diagnostique, dans laquelle R¹ représente

His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-,
5 10 15 20

30 et R² représente OH, la chaîne peptidique

-Phe-Val-Gln-Trp-Leu
25

35 ou -Met-Asn-Thr ou une chaîne peptidique correspondante ou un amino-acide qui est identique aux deux
chaînes peptidiques mentionnées en dernier lieu mis à part le fait que l'un ou plusieurs des acides aminés
des deux chaînes peptidiques mentionnées en dernier lieu a/ont été omis, ou un sel de ceux-ci.

2. Composé selon la revendication 1, utilisé à titre de médicament ou d'agent diagnostique caractérisé
40 en ce que le composé est utilisé en tant qu'agent spasmolytique ou en tant qu'inhibiteur de la sécrétion
d'acide gastrique.

3. Composé selon la revendication 1, utilisé à titre de médicament ou d'agent diagnostique caractérisé
en ce que le composé est utilisé pour le traitement de spasmes du système digestif, pour le traitement du
tractus biliaire et des calculs des voies urinaires et/ou pour le traitement des ulcères dans l'appareil
gastro-duodéal.

45 4. Composé selon l'une quelconque des revendications 1 à 3, utilisé à titre de médicament ou d'agent
diagnostique, caractérisé en ce que R² représente OH,

-Phe-Val-Gln-Trp-Leu
25

50 ou

-Met-Asn-Thr.

5. Composé selon l'une quelconque des revendications 1 à 3, utilisé à titre de médicament ou d'agent
diagnostique, caractérisé en ce que R² représente OH.

55 6. Composition pharmaceutique contenant une quantité efficace du composé de formule I de la
revendication 1 ou un sel de celui-ci, en association avec un support adéquat, physiologiquement
acceptable, un diluant et/ou un excipient.

7. Composition pharmaceutique selon la revendication 6 contenant 7,5 à 75 000 µg, de préférence 75 à
7500 µg du composé de formule I, ou un sel de celui-ci, par dose unitaire.

60 8. Composition pharmaceutique selon la revendication 6 ou 7 dans laquelle R² représente OH,

-Phe-Val-Gln-Trp-Leu
25


ou

65 -Met-Asn-Thr.

9. Composition pharmaceutique selon la revendication 6 ou 7 dans laquelle R² est OH.
10. Composé nouveau de formule générale I'



5 dans laquelle R¹ a la même signification que celle définie à la revendication 1, et R² a la même signification que R² à la revendication 1, mis à part le fait que R² ne représente pas Phe-Val, Phe-Val-Gln-Trp,




ou OH, ou un sel d'un tel composé.

Revendications pour l'état Contractant: AT

15 1. Procédé de fabrication d'une préparation pharmaceutique destinée à être utilisée comme médicament ou comme agent diagnostique, ledit procédé consistant à incorporer, dans une préparation pharmaceutique, un composé de formule générale I



dans laquelle R¹ représente



et R² représente OH, la chaîne peptidique



ou -Met-Asn-Thr ou une chaîne peptidique correspondante ou un aminoacide qui est identique aux deux chaînes peptidiques mentionnées en dernier lieu mis à part le fait que l'un ou plusieurs des acides aminés des deux chaînes peptidiques mentionnées en dernier lieu a/ont été omis, ou un sel de ces composés.

35 2. Procédé selon la revendication 1, dans lequel la préparation pharmaceutique est utilisée en tant qu'agent spasmolytique ou en tant qu'inhibiteur de la sécrétion d'acide gastrique.

3. Procédé selon la revendication 1, dans lequel la préparation pharmaceutique est utilisée pour le traitement de spasmes du système digestif, pour le traitement du tractus biliaire et des calculs des voies urinaires et/ou pour le traitement des ulcères dans l'appareil gastro-duodéal.

40 4. Procédé selon l'une quelconque des revendications 1 à 3 dans lequel R² représente OH, -Phe-Val-Gln-Trp-Leu ou -Met-Asn-Thr.

5. Procédé selon l'une quelconque des revendications 1 à 4 dans lequel R² représente OH.

45 6. Composition pharmaceutique contenant une quantité efficace du composé de formule I de la revendication 1 ou un sel de celui-ci, en association avec un support adéquat, physiologiquement acceptable, un diluant et/ou un excipient.

7. Composition pharmaceutique selon la revendication 6 contenant 7,5 à 75 000 µg, de préférence 75 à 7500 µg d'un composé de formule I, ou un sel de celui-ci, par dose unitaire.


50 8. Composition pharmaceutique selon la revendication 6 ou 7 dans laquelle R² représente OH, -Phe-Val-Gln-Trp-Leu ou -Met-Asn-Thr.

9. Composition pharmaceutique selon la revendication 6 ou 7 dans laquelle R² est OH.

10. Composé nouveau de formule générale I':



55 dans laquelle R¹ a les mêmes significations que celle définie à la revendication 1 et R² a la même signification que R² à la revendication 1, mis à part le fait que R² ne représente pas



ou OH, ou un sel d'un tel composé.




65 11. Procédé de préparation du composé de formule I' ou un sel de celui-ci, consistant à préparer ledit composé à partir du L-aminoacide de départ, après quoi le composé de formule I' est éventuellement transformé en un sel de celui-ci.

0 044 168

12. Procédé de préparation d'un composé de formule I' ou d'un sel de celui-ci, dans lequel un composé de formule générale



5 dans laquelle R³ représente



R⁴ représente la fraction peptidique



dont un ou plusieurs acides aminés a/ont été omis, la fraction peptidique -Met-Asn-Thr(Bu¹)- ou les fractions peptidiques correspondantes qui sont identiques à ladite fraction, mis à part le fait que l'un ou plusieurs des acides aminés a/ont été omis, X représentant le chlore ou le brome, est traité avec un acide tel que l'acide trifluoroacétique, après quoi le composé obtenu est éventuellement transformé en un sel de celui-ci.

30

35

40

45

50

55

60

65